论文部分内容阅读
目的探讨P-糖蛋白(P-gp),谷胱甘肽S转移酶π(GST-π),DNA拓扑异构酶Ⅱ(TopoⅡ)在乳腺癌组织中的表达及其意义。方法采用免疫组化SP法对78例术前未行化疗患者的乳腺癌组织切片中P-gp、GST-π、TopoⅡ的表达进行分析。结果P-gp、GST-π、TopoⅡ的阳性表达率分别为38.5%、46.2%、73.1%,与年龄、肿瘤大小、ER/PR和HER2状况无关。腋淋巴结阳性组P-gp和GST-π的阳性表达率与阴性组比较,差异有统计学意义(2χ=5.175,2χ=4.614,P<0.05);肿瘤不同分期的P-gp的阳性表达率差异有统计学意义(2χ=5.848,P<0.05)而且随分期增高而增高。结论乳腺癌组织的原发多药耐药与P-gp、GST-π、TopoⅡ的表达有关,化疗前对它们进行检测可为化疗药物的选择及预后判断提供参考依据。
Objective To investigate the expression and significance of P-glycoprotein (P-gp), glutathione S transferase π (GST-π) and DNA topoisomerase II (Topo II) in breast cancer. Methods Immunohistochemical SP method was used to analyze the expression of P-gp, GST-π and Topo II in 78 breast cancer patients who had not undergone chemotherapy before operation. Results The positive rates of P-gp, GST-π, and TopoII were 38.5%, 46.2%, and 73.1%, respectively, which were independent of age, tumor size, ER/PR, and HER2 status. The positive expression rate of P-gp and GST-π in the axillary lymph node positive group was significantly lower than that in the negative group (2χ=5.175, 2χ=4.614, P<0.05); the positive expression rate of P-gp in different stages of tumors The difference was statistically significant (2χ=5.848, P<0.05) and increased with the increase of the stage. Conclusion The primary multidrug resistance of breast cancer tissues is related to the expression of P-gp, GST-π and Topo II. The detection of them before chemotherapy can provide reference for the selection of chemotherapy drugs and prognosis.